Carol Brosgart, MD
Dr. Brosgart is a Clinical Professor of Medicine, Biostatistics and Epidemiology at UC San Francisco. Dr. Brosgart serves on numerous boards of both public and privately-held biotechnology companies and consults for multiple to global biopharmaceutical companies. She has also served on senior US Government committee and held numerous senior management positions in healthcare and biotechnology. At Gilead, she was responsible for development and FDA approval of Viread® for the treatment of HIV, and Hepsera® for the treatment of Chronic Hepatitis B. Dr. Brosgart has decades of experience across public health, clinical care, research, development, and teaching. Dr. Brosgart received her M.D. from UC San Francisco as well as her residency training in Pediatrics (UCSF) and Public Health and Preventive Medicine at UC Berkeley. She has published extensively in the areas of infectious diseases, focusing on antiviral therapy for HIV, HBV, CMV, and related public health policy.